Curetis attaches great importance to validating its products according to international standards. Studies are currently underway in the USA and Europe and additional studies are being prepared to evaluate the medical and economic benefits of rapid multiplex PCR tests on infectious disease following market introduction.

You can find publications on the various studies here.

The following studies are currently underway:

Unyvero Pneumonia Application 

  • A prospective, multicenter study with over 2,200 patient samples has been completed and results have been submitted to the FDA for clearance
  • Pan-European clinical study with a leading pharmaceutical company

Unyvero ITI Application

Completed Studies:

The Curetis GmbH has successfully concluded 30 studies with Unyvero, including data from over 4,000 tested patient samples.

Unyvero Pneumonia Application

  • CE performance evaluation study with 392 patient samples
  • Prospective multicenter EU study with 822 patient samples
  • Clinical evaluations (e.g. in Munich, Basel, Kuwait, Chicago and Maastricht)
  • Research-based studies in pediatrics in Germany, Austria and Switzerland

Unyvero ITI Application

  • CE performance evaluation study with 339 patient samples
  • Clinical evaluation (for example Madrid, Freiburg, Bonn, Nantes)